2024-07-26 15:10:34 ET
Summary
- AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments.
- Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024.
- The global Alzheimer's therapeutics market size is expected to surpass $8.18 billion by 2032.
- Interim safety and immunogenicity data from the phase 2 VacSYn trial, using ACI-7104.056 for the treatment of patients with Parkinson's Disease, is expected in the second half of 2024.
The last time I wrote about AC Immune SA ( ACIU ), it was in a Seeking Alpha article entitled “ AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts. ” In this article, I wrote about the prospects of its anti-Abeta active immunotherapy ACI-24.060 immunotherapy candidate being used to treat patients with Alzheimer's Disease [AD]. The use of this vaccine immunotherapy is currently being explored in the ongoing phase 2 ABATE trial. This trial is split up into targeting AD patients and also non-demented adults with Down Syndrome [DS]. Having said that, there are two catalysts expected from this specific phase 2 program using ACI-24.060 for the treatment of these patients. The first of which is that there will be updated guidance given for when interim results from the ABATE trial are to be released. Such guidance is expected to occur in the 2nd half of 2024....
Read the full article on Seeking Alpha
For further details see:
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward